GMO regulations a ‘significant burden’ on gene therapy clinical trials – OutSourcing-Pharma.com
OutSourcing-Pharma.com |
GMO regulations a ‘significant burden’ on gene therapy clinical trials
OutSourcing-Pharma.com The Alliance for Regenerative Medicine (ARM) and other industry groups are urging regulators to consider gene therapy requirements in upcoming reforms, because some advanced therapy medicinal products (ATMPs), such as gene therapies, contain … |
Lymphoma News Today |
CAR T-cells Targeting CD20-positive Non-Hodgkin’s Lymphoma Safe and Effective, Long-term Study Shows
Lymphoma News Today A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin’s lymphoma with CD20-carrying B-cells show the approach is similar in effectiveness and safety to the more common CAR T-cell therapy. The study, published … |
Forbes |
Here Come More Gene Therapies — And More Pricing Debates
Forbes The Food and Drug Administration approved the first gene therapy in August and is considering another for approval soon. Designed as one-time treatments, they don’t come cheap, and that’s raising concerns among health care payers. (AP Photo/Andrew … Gene Therapy for Blindness Appears Initially Effective, Says US FDAScientific American The FDA is Considering a Landmark Approval of Gene Therapy to …Gizmodo With AdComm meeting looming, FDA shares concerns about Spark’s lead gene therapyFierceBiotech ABC News –Business Insider –WebMD all 63 news articles » |